Efficacy of Spironolactone on Survival in Dogs with Naturally Occurring Mitral Regurgitation Caused by Myxomatous Mitral Valve Disease

Bernay, Florence; Bland, Martin; Häggström, Jens; Baduel, Lauree; Combes, Bruno; Lopez, A; Kalsatos, V

doi:10.1111/j.1939-1676.2009.0467.x

Research article2010Peer reviewedOpen access

Efficacy of Spironolactone on Survival in Dogs with Naturally Occurring Mitral Regurgitation Caused by Myxomatous Mitral Valve Disease

Bernay, Florence; Bland, Martin; Häggström, Jens; Baduel, Lauree; Combes, Bruno; Lopez, A; Kalsatos, V

Abstract

Spironolactone added to conventional cardiac therapy decreases the risk of reaching the primary endpoint (ie, cardiac-related death, euthanasia, or severe worsening) in dogs with moderate to severe MR caused by MMVD.

Keywords

Canine; Clinical trial; Evidence based medicine; Heart failure

Published in

Journal of Veterinary Internal Medicine
2010, volume: 24, number: 2, pages: 331-341
Publisher: WILEY-BLACKWELL PUBLISHING, INC

SLU Authors

Häggström, Jens
- Department of Clinical Sciences, Swedish University of Agricultural Sciences

UKÄ Subject classification

Animal and Dairy Science
Veterinary Science

Publication identifier

DOI: https://doi.org/10.1111/j.1939-1676.2009.0467.x

Permanent link to this page (URI)

https://res.slu.se/id/publ/48529